Skip to content

Assessment of Clinical Effects of Coenzyme Q10 Levels in COVID-19 Patients in Intensive Care Unit

Our Study Will be Carried Out in Hacettepe University Anesthesiology and Reanimation Intensive Care Unit. COVID-19 Positive or Suspected Patients Will be Admitted to the Unit. Coenzyme Q10 Levels Will be Checked in the First Day of Hospitalization and Once a Week. The Relationship Between Results and Clinical Course Will be Evaluated.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05058716
Enrollment
150
Registered
2021-09-28
Start date
2021-01-01
Completion date
2022-12-01
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The study will be done in Hacettepe University Anesthesiology and Reanimation Intensive Care Unit. The investigators will accept COVID-19 diagnosed or suspected patients to the ICU. In the first day of hospitalization and after that once a week, the investigators will take blood samples from the patients to evaluate Coenzyme q10 levels. Our hypothesis is that there is a relationship between low coenzyme q10 levels and poor clinical outcome.

Interventions

DIAGNOSTIC_TESTblood sample

weekly blood sample - coenzym q10 levels

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\-

Exclusion criteria

* being under the age of 18 * being pregnant * patient refusal

Design outcomes

Primary

MeasureTime frameDescription
mortalityfrom the first day of hospitalization until the date of death from any causeyes or no
duration of mechanical ventilationfrom the first day of hospitalization and during ICU stay perioddays
duration of vasopressor agent requirementfrom the first day of hospitalization and during ICU stay perioddays

Secondary

MeasureTime frameDescription
any organ failurefrom the first day of hospitalization until the date of death from any cause or discharge from ICUyes or no
hospital stay periodfrom the first day of discharge from ICU to ward until the date of death or discharge from the hospitaldays
new thromboembolic eventfrom the first day of hospitalization until the date of death from any cause or discharge from ICUyes or no
ICU stay periodfrom the first day of hospitalization until the date of death from any cause or discharge from ICUdays

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026